Avidity Biosciences Reports Third Quarter 2024 Financial Results and Recent Highlights

Enrollment in global Phase 3 HARBOR™ study for del-desiran in DM1 is on trackAvidity initiated biomarker cohort for del-brax FORTITUDE™ study for FSHD; pursuing a potential accelerated approval path for del-braxReported positive del-zota data from Phase 1/2 EXPLORE44™ trial for DMD44Avidity to provide a first look at precision cardiology candidates and a glimpse at next-generation technology innovations via webcast event November 12, 2024SAN DIEGO, Nov. 7, 2024 /PRNewswire/ -- Avidity Biosciences, Inc. (Nas ...